Biotechnology, Healthcare, and Research by Vertex Pharmaceuticals
498.83
13.61
2.80 %
At close
10/14
USD
Daily range
489.98
502.79
502.79
Weekly range
484.99
514.71
514.71
Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
Vertex Pharmaceuticals (VRTX) stock is trading at $490.47, down 3.26% today. The price currently sits below its key moving averages, indicating short-term weakness while ...
VRTX drops as $10B Crinetics Pharmaceuticals acquisition raises risk
Vertex Pharmaceuticals (VRTX) stock is trading at $506.3, down 3.17% for the day. The price is currently positioned below its key moving averages, reflecting short-term ...
Vertex Pharmaceuticals enters reimbursement agreement for cystic fibrosis therapy after muted trading session
Vertex Pharmaceuticals has entered a new reimbursement agreement for its latest cystic fibrosis therapy in Estonia, announced September 11, 2026. Separately, the stock edges higher on the day, ...
Vertex Pharmaceuticals announces positive study results and trial enrollment after muted trading session
Vertex Pharmaceuticals announced positive Phase 2b results for its AMPLIFIED study and completed enrollment in a separate late-stage trial for APOL1-mediated kidney disease. The stock edges higher ...
Why is Vertex Pharmaceuticals stock down 3.1% today?
Vertex Pharmaceuticals Incorporated (VRTX) declined 3.13% as technical indicators point to near-term exhaustion and selling pressure. The down move is supported by the stock slipping below its ...
Vertex Pharmaceuticals enters new reimbursement agreement for cystic fibrosis therapy after stock ends session up 1%
Vertex Pharmaceuticals has secured a reimbursement agreement for its recent cystic fibrosis therapy in Latvia. The stock is up 1% on the day at $553.04.Vertex Pharmaceuticals has entered a new ...
Vertex stock gains as Uruguay expands access to cystic fibrosis treatment
Vertex Pharmaceuticals announced it has extended its reimbursement agreement with Uruguayan health authorities, giving broader access to its cystic fibrosis medicine for eligible children. The ...
Vertex Pharmaceuticals shares drop over 4% after Crinetics Pharmaceuticals $10B all-cash acquisition news
Vertex Pharmaceuticals (VRTX) stock is trading at $500.45, down 4.18% for the day and sitting near the session low with moderate volatility. The price is currently below ...
Vertex Pharmaceuticals stock trades up to $529.75 as VertexPharma announces Crinetics acquisition
Vertex Pharmaceuticals announced an agreement to acquire Crinetics.Vertex Pharmaceuticals stated that this deal adds to its portfolio of transformative medicines. The company said the move ...
Rockefeller Capital stake increase propels Vertex Pharmaceuticals stock higher by 3.42%
Vertex Pharmaceuticals Incorporated (VRTX) stock is trading at $467.2, up 3.42% on the day and sitting above its key moving averages. The stock is showing notable ...
Why is Vertex Pharmaceuticals stock up today?
Vertex Pharmaceuticals Incorporated (VRTX) rose 2.74% after strong institutional activity, as Rockefeller Capital Management significantly increased its stake in the company. The advance is ...
Vertex Pharmaceuticals stock remains under pressure after regulatory submission update and continued weekly decline
Vertex Pharmaceuticals presented data on its gene-edited therapy for people with sickle cell disease or transfusion-dependent beta thalassemia at the European Hematology Association Congress.The ...
Vertex Pharmaceuticals stock consolidates near highs after North Macedonia reimbursement agreement extension
Vertex Pharmaceuticals has extended its reimbursement agreement with the National Health Insurance Fund in North Macedonia.Since May 20, 2026, eligible people living with cystic fibrosis age 2 ...
Sustained momentum drives Vertex Pharmaceuticals stock higher despite signs of overbought conditions
Vertex Pharmaceuticals (VRTX) stock is trading at $446.58, up 4.26% on the day. The current price sits above its key moving averages, reflecting continued upward ...
Why is Vertex Pharmaceuticals stock down today?
Vertex Pharmaceuticals Incorporated (VRTX) closed at $427.91, reflecting a decline of $10.62 or 2.42% for the day. The stock remains below its 20-day, 50-day, and 200-day moving averages, ...
Vertex Pharmaceuticals shares dip amid rising selling pressure
Vertex Pharmaceuticals Incorporated (VRTX) currently trades at $436.80, down 2.39% for the day after opening with a downside gap. The price remains above both the 20-day and 200-day moving ...
Buying pressure lifts Vertex Pharmaceuticals stock higher in today's trading
Vertex Pharmaceuticals Incorporated (VRTX) is trading at $447.15, up 2.27% for the day. The stock is positioned above the 20-day ($433.88), 50-day ($439.03), and 200-day ($435.40) simple moving ...
$440–$445 resistance stalls Vertex Pharmaceuticals stock advance
Vertex Pharmaceuticals (VRTX) stock is trading at $436.11, marking a daily gain of 0.35%. The current price is positioned above its short-term moving average while ...
